Evidence map›Paper›PMID 34669176›Full record

ArticleImmunologic research2022

Efficiency and safety of eltrombopag for multi-line failed Chinese patients with immune thrombocytopenia: cases with decreased megakaryocyte response well from single-center experience.

Qi Liu, Yingying Shen, Yuzhu Li, Huijin Hu, Wenbin Liu, Yuechao Zhao, Huijie Dong, Yiping Shen, Yuhong Zhou, Baodong Ye and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Qi LiuThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yingying ShenThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yuzhu LiThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Huijin HuThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Wenbin LiuThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yuechao ZhaoThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Huijie DongThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yiping ShenThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yuhong ZhouThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Baodong YeThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. 13588453501@163.com.
Dijiong WuThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. wudijiong@zcmu.edu.cn.ORCID 0000-0003-2338-9365
Zhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune thrombocytopenia (ITP) was defined using the International Consensus Guidelines as a platelet count <100×10

Indexed as

Purpura, Thrombocytopenic, IdiopathicThrombocytopeniaBenzoatesChinaHumansHydrazinesMegakaryocytesPyrazolesRetrospective StudiesBenzoateseltrombopagHydrazinesPyrazolesEltrombopagImmune thrombocytopeniaLymphocyte subsetsMegakaryocytePredictive markers

Identifiers

PMID34669176
OpenAlexW3206571950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.